ATAI•benzinga•
Atai Life Sciences Announced The Completion Of Patient Enrollment In The Eight-week, Double-blind, Core Stage Of The Global Phase 2B Clinical Trial Evaluating Bpl-003 (Mebufotenin Benzoate) In Patients With Treatment-resistant Depression (TRD)
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 5, 2025 by benzinga